Introduction Drugs used to treat hormone receptor-positive breast cancer can be divided into two classes (Pickar et al., 2010; Yu et al., 2012) : the selective estrogen receptor modulators (SERMs), and the aromatase inhibitors (AIs). Both classes of drugs are designed to interfere with the effects of estrogen, which plays an important role in the development and proliferation of breast cancer.
SERMs reduce estrogenic effects by antagonism of estrogen binding to the estrogen receptors (ERs), while AIs act by reducing the generation of estrogens from androgens via aromatase (CYP19) (Ziller et al., 2009 ). The conversion of testosterone to estradiol by aromatase (CYP19) is the main source of endogenous estrogen in post-menopausal women (Subbaramaiah et al., 2008) .
Tamoxifen is the most widely used SERM that is approved by the FDA (the United States Food and Drug Administration). It has a complex metabolic profile involving both active and inactive metabolites (Jin et al., 2005) . Previous studies have shown that two tamoxifen metabolites, Ndesmethyltamoxifen (N-DMT) and endoxifen, can act as AIs in vitro (Lu et al., 2012a) . Recently, norendoxifen, another active metabolite of tamoxifen, has also been shown to be a potent AI.
Norendoxifen inhibited recombinant aromatase (CYP19) via a competitive mechanism with an IC 50 of 90 nM and inhibited human liver CYP2C9 with an IC 50 of 990 nM. In this first study published, the inhibition of CYP2C19 activity by norendoxifen in human liver microsomes using R-omeprazole as a substrate probe was very weak, with less than 25% enzyme activity reduced when the concentration of norendoxifen was 5 μM. No inhibition of CYP2B6 or CYP2D6 by 5 μ M norendoxifen was detected (Lu et al., 2012b) .
Norendoxifen has been identified as a promising new class of aromatase inhibitors (AIs) under development, and it should be evaluated for drug-drug interactions as a proposed new drug that undergoes significant metabolism by the cytochrome P450 system. In the development of any
5 new therapeutic drug that undergoes metabolism, it is important to understand which enzyme is involved in the metabolic disposition. Since this may influence our understanding of bioavailability of drug-drug interactions and of pharmacogenetic effects. The cytochrome P450
superfamily consists of a large group of enzymes, including aromatase (CYP19), CYP1A2, CYP2A6, CYP3A4, CYP3A5, CYP2B6, CYP2C9, CYP2C19 and CYP2D6, which are important in clinical drug-drug interactions and in drug metabolism (Stearns et al., 2003; Ward et al., 2004; Flockhart et al., 2008; Jeong et al., 2009; Kamdem et al., 2011) . About 90% of human drug oxidation can be attributed to CYP1A2, CYP2A6, CYP3A4, CYP3A5, CYP2C9 and CYP2C19 (Rendic, 2002) . In this context, the inhibitory ability of norendoxifen against CYP1A2, CYP2A6, CYP3A4 and CYP3A5 has not been described. Since both IC 50 and K i values are important descriptions for drug-enzyme interactions, it follows that further studies are required to determine the effects of norendoxifen on these enzymes. The IC 50 and K i values of norendoxifen against recombinant aromatase (CYP19), CYP1A2, CYP2A6, CYP3A4, CYP3A5 and CYP2C19
were tested using microsomal incubations to determine the effects of norendoxifen as a cytochrome P450 inhibitor for these enzymes. The double bond in norendoxifen leads to E-and Z-isomers, which may possess different inhibitory activities against different cytochromes P450 due to their different chemical structures. The chemical structures of the E-and Z-isomers of norendoxifen are shown in Figure 1 . In order to investigate the inhibitory specificity of the E-and Z-norendoxifen, we determined their IC 50 and K i values against recombinant aromatase (CYP19), CYP1A2, CYP3A4, CYP3A5 and CYP2C19 in the same way using microsomal incubations. In this way, the isomers' selective effects of norendoxifen were determined.
Materials and Methods
Chemicals and Reagents. The E-, mixed and Z-norendoxifen were provided by Dr. Mark Cushman (Purdue University, West Lafayette, IN). The chemical makeup of the E-norendoxifen described in the studies is 100:1 E/Z, whereas the Z-isomer is 1:10 E/Z. They were stored at -20℃ without light. Cytochrome P450 (CYP) inhibitor screening kits of aromatase (CYP19), CYP1A2, CYP2A6, CYP3A4, CYPA3A5 and CYP2C19 were purchased from BD Biosciences (San Jose, CA).
Inhibition of Recombinant Human Cytochrome P450 Enzymes by Microsomal Incubations.
The activity of each recombinant human cytochrome P450 enzyme was determined by measuring the conversion rate of a fluorometric substrate to its fluorescent metabolite. The activity of aromatase (CYP19) was determined using the metabolism of 7-methoxy-4-trifluoromethylcoumarin (MFC) to 7-hydroxy-4-trifluoromethylcoumarin (HFC). The activities of CYP1A2 and CYP2C19 were determined using the metabolism of 3-cyano-7-ethoxycoumarin (CEC) to 3-cyano-7-hydroxycoumarin (CHC). The activity of CYP2A6 was determined using the metabolism of coumarin to 7-hydroxycoumarin (HC). The activities of CYP3A4 and CYP3A5
were determined using the metabolism of 7-benzyloxy-4-trifluoromethyl-coumarin (BFC) to 7-hydroxy-4-trifluoromethylcoumarin (HFC). Experimental procedures were essentially as described previously (Lu et al., 2011) . All the incubations were performed using incubation times and protein concentrations that were within the linear range for reaction velocity. 
Results
To test the potency of mixed norendoxifen against aromatase (CYP19) and understand whether the inhibitory ability of norendoxifen on aromatase (CYP19) extends to other important drugdrug interaction and drug-metabolizing enzymes in the cytochrome P450 superfamily, the inhibition of cytochrome P450 enzymes by norendoxifen, including aromatase (CYP19), CYP1A2, CYP2A6, CYP3A4, CYP3A5 and CYP2C19, were tested using microsomal incubations. 3-Cyano-7-ethoxycoumarin (CEC) was used as a substrate probe for CYP2C19 to further explore the possibility of substrate probe-dependent inhibition. Figure 2 and Table 1 show the inhibitory potency of norendoxifen against these enzymes. The order of inhibitory potency of norendoxifen against these enzymes was as follows: recombinant CYP2C19 > To explore the inhibitory mechanism employed by norendoxifen, the inhibitory effects of E-, mixed and Z-norendoxifen were tested against recombinant aromatase (CYP19), CYP1A2, CYP3A4, CYP3A5 and CYP2C19 across a range of fluorometric substrate concentrations (Table 3 ). E-, mixed and Z-norendoxifen inhibited recombinant aromatase (CYP19) via a competitive mechanism with K i values of 48 ± 3 nM, 70 ± 9 nM and 445 ± 6 nM, respectively. 
Discussion
The current third generation AIs, including letrozole, anastrozole and exemestane, are demonstrably superior to tamoxifen as agents to reduce the recurrence of breast cancer in postmenopausal women (ATAC, IES, BIG-98). Their efficacy is limited, however, by toxicities that reduce quality of life and compromise compliance (Santoro et al., 2011; Thompson et al., 2011) .Obviously, new aromatase inhibitors (AIs) with less toxicity are needed to allow better treatment of hormone receptor-positive breast cancer in post-menopausal women. We identified a new aromatase inhibitor (AI), namely norendoxifen. Norendoxifen becomes an attractive lead compound for new class of aromatase inhibitors (AIs) for two unique features. On one hand, the potent inhibitory ability of norendoxifen is efficiently able to reduce estrogen biosynthesis in the breast to inhibit the tumor growth, while, its estrogen receptor modulatory ability make it possible to ameliorate the side effects in bone and other tissues caused by estrogen depletion.
On the other hand, since norendoxifen is a metabolite of the most widely used selective estrogen receptor modulator (SERM), tamoxifen, lots of patients have already been exposed to it (Lv et al., 2013) . The bioavailability and relative safety of norendoxifen hold more confidence than other lead compounds under development.
The metabolism of tamoxifen results in two main metabolites, N-desmethyltamoxifen (N-DMT)
and Z-4-hydroxytamoxifen (Z-4HT). N-DMT is converted into endoxifen, a minor metabolite, mainly by CYP2D6, while, Z-4HT is converted into endoxifen mainly by CYP3A4 and CYP3A5 (Del Re et al., 2012) . Endoxifen is demethylated to norendoxifen via a metabolic route that is still unknown. Among tamoxifen metabolites, 4HT and endoxifen have been shown to be selective estrogen receptor modulators (SERMs), serving as antagonists of estrogen binding to the estrogen receptors (ERs) (Lim et al., 2005) . N-DMT and endoxifen act as AIs with IC 50 values of 6.1 μM and 20.7 μM, respectively, via noncompetitive mechanisms (Lu et al., 2012a) .
In previous studies, we have characterized the inhibitory ability of norendoxifen against recombinant aromatase (CYP19), CYP2B6, CYP2D6, human liver CYP2C9 and CYP2C19.
Other members of the cytochrome P450 superfamily, including CYP1A2, CYP2A6, CYP3A4 and CYP3A5, also play important roles. In human liver, CYP1A2 accounts for 13% of the Any proposed new drug that undergoes significant metabolism by the cytochrome P450 system should be evaluated for drug-drug interactions. In this study, we tested mixed norendoxifen's effects on the inhibition of important cytochrome P450 enzymes, which were not studied before, including CYP1A2, CYP2A6, CYP3A4 and CYP3A5. To verify the inhibition profiles of CYP2C19 are dependent on a specific inhibitor-substrate interaction, 3-cyano-7-ethoxycoumarin (CEC) was used as another substrate probe compared with R-omeprazole.
A previous study showed substrate-dependent inhibition of CYP2C19, when S-mephenytoin, Romeprazole, S-omeprazole and S-fluoxetine were used as substrates (Foti and Wahlstrom, 2008) . Our studies with R-omeprazole and CEC confirmed that inhibition of CYP2C19 is substrate dependent. CEC has high sensitivity to in vitro inhibition of CYP2C19, while, no inhibition was observed using R-omeprazole as substrate. An analysis of homology models of CYP2C enzymes reveals more than one binding region within the active site, and this may be
the mechanism that underlies substrate-dependent inhibition seen (Ridderstrom et al., 2001) .It is also possible that the differences in incubation conditions, such as enzyme sources, incubation times, and measurement methods may also contribute to the different inhibition profiles that we observed.
Further study was conducted on testing the inhibitory activities of E-and Z-norendoxifen against aromatase (CYP19), CYP1A2, CYP3A4, CYP3A5 and CYP2C19. Norendoxifen has high isomer's selectivity against aromatase (CYP19). E-norendoxifen had 9.3-fold higher inhibitory ability than Z-norendoxifen against aromatase (CYP19). E-norendoxifen inhibited CYP1A2 and CYP3A4 2.0-fold and 3.7-fold, respectively, more potently than Z-norendoxifen. E-and Znorendoxifen had similar inhibitory ability against CYP3A5 and CYP2C19. The double bond of norendoxifen does have a significant impact on the inhibitory activities of its E-and Z-isomers against aromatase (CYP19).
As a minor metabolite of tamoxifen, norendoxifen turns out to be the most potent AI among the known metabolites that we have tested. The data reveal a complex metabolism of tamoxifen that may lead to some metabolites that are able to inhibit aromatase (CYP19) or act as a SERM or combine both of these activities. Since endoxifen functions both as a SERM and an AI, norendoxifen may also be an antagonist to estrogen receptors (ERs) due to their similar chemical structures. Also, the contribution of norendoxifen to the overall effects of tamoxifen remains unknown and its concentration in patients is not well defined. Studies have showed that endoxifen has low concentration in plasma, however, the tissue concentrations of endoxifen are higher, appearing to be 10-100 times more (Lien et al., 1991) . Norendoxifen has the potential to be a therapeutically useful AI with fewer side effects, and in the meantime, it provides a new lead compound for the rational design of a series of novel compounds with dual aromatase inhibitory activity and estrogen receptor modulatory activity.
The high selectivity of E-norendoxifen also provides new information for the development of potent AIs. While the main form of norendoxifen as the metabolite of tamoxifen in human body is the Z-isomer, the toxicity and metabolism of the E-isomer deserve more study. Each point represents one incubation, and two independent incubations were conducted for each concentration of norendoxifen and substrate. 
